Condition

Urothelial Carcinoma Bladder

ClinicalTrials.gov condition label

Clinical trials7

Recruiting2

Common interventions10

Lead sponsors shown7

Clinical trials

7 shown

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid TumorsNCT07020117 · 2025-08-22

A Study of VET3-TGI in Patients With Solid TumorsNCT06444815 · 2024-09-16

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4NCT07218003 · 2025-11-17

ENROLLING_BY_INVITATION

Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid TumorsNCT06714617 · 2025-04-10

Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02)NCT05520099 · 2023-06-26

ACTIVE_NOT_RECRUITING

IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBCNCT05077709 · 2022-04-11

Phase Ib of L-NMMA and PembrolizumabNCT03236935 · 2018-08-27

Common interventions

PembrolizumabDRUG2 [225Ac]Ac-AKY-1189 (therapeutic)DRUG1 [64Cu]Cu-AKY-1189 (imaging)DRUG1 AtezolizumabDRUG1 BL-M17D1DRUG1 Core Needle Biopsy, Forceps Biopsy, Punch BiopsyPROCEDURE1 IO102-IO103 in combination with pembrolizumabDRUG1 L-NMMADRUG1 RNDO-564DRUG1 VET3-TGIDRUG1

Leading sponsors

Aktis Oncology, Inc.1 Elephas1 IO Biotech1 KaliVir Immunotherapeutics1 Rondo Therapeutics1 SystImmune Inc.1 The Methodist Hospital Research Institute1

Trial status mix

COMPLETED2

RECRUITING2

ACTIVE_NOT_RECRUITING1

ENROLLING_BY_INVITATION1

TERMINATED1

Phase mix

PHASE15

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.